These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 25444677)

  • 1. Continued effectiveness of laninamivir octanate hydrate for influenza treatment in Japan: comparison between the 2011-2012 and 2012-2013 influenza seasons.
    Ikematsu H; Kawai N; Iwaki N; Kashiwagi S
    J Infect Chemother; 2014 Dec; 20(12):799-803. PubMed ID: 25444677
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The duration of fever and other symptoms after the initiation of laninamivir octanoate hydrate in the Japanese 2011-2012 influenza season.
    Ikematsu H; Kawai N; Iwaki N; Kashiwagi S
    J Infect Chemother; 2014 Feb; 20(2):81-5. PubMed ID: 24486167
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical outcome of laninamivir octanoate hydrate for influenza in the 2013-2014 Japanese season.
    Ikematsu H; Kawai N; Iwaki N; Kashiwagi S
    J Infect Chemother; 2015 Nov; 21(11):802-7. PubMed ID: 26410550
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Duration of fever and other symptoms after the inhalation of laninamivir octanoate hydrate for influenza treatment; comparison among the four Japanese influenza seasons from 2011-2012 to 2014-2015.
    Ikematsu H; Kawai N; Iwaki N; Kashiwagi S
    J Infect Chemother; 2016 Sep; 22(9):605-10. PubMed ID: 27493024
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Duration of fever and other symptoms after the inhalation of laninamivir octanoate hydrate; comparison of the 2011/12 to 2015/16 Japanese influenza seasons.
    Ikematsu H; Kawai N; Iwaki N; Kashiwagi S
    J Infect Chemother; 2017 Sep; 23(9):627-633. PubMed ID: 28709902
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Duration of fever and other symptoms after the inhalation of laninamivir octanoate hydrate in the 2016/17 Japanese influenza season; comparison with the 2011/12 to 2015/16 seasons.
    Ikematsu H; Kawai N; Iwaki N; Kashiwagi S; Ishikawa Y; Yamaguchi H; Shiosakai K
    J Infect Chemother; 2018 Sep; 24(9):718-724. PubMed ID: 29861186
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical effectiveness of neuraminidase inhibitors--oseltamivir, zanamivir, laninamivir, and peramivir--for treatment of influenza A(H3N2) and A(H1N1)pdm09 infection: an observational study in the 2010-2011 influenza season in Japan.
    Shobugawa Y; Saito R; Sato I; Kawashima T; Dapat C; Dapat IC; Kondo H; Suzuki Y; Saito K; Suzuki H
    J Infect Chemother; 2012 Dec; 18(6):858-64. PubMed ID: 22644080
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Duration of fever and other symptoms after the inhalation of laninamivir octanoate hydrate: A study of the 2017/18 and 2018/19 seasons and comparison with the 2011/12 to 2016/17 Japanese influenza seasons.
    Tani N; Kawai N; Ikematsu H; Bando T; Iwaki N; Takasaki Y; Shindo S; Chong Y; Kashiwagi S
    J Infect Chemother; 2022 Jul; 28(7):890-895. PubMed ID: 35317975
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neuraminidase inhibitor susceptibility profile of pandemic and seasonal influenza viruses during the 2009-2010 and 2010-2011 influenza seasons in Japan.
    Dapat C; Kondo H; Dapat IC; Baranovich T; Suzuki Y; Shobugawa Y; Saito K; Saito R; Suzuki H
    Antiviral Res; 2013 Sep; 99(3):261-9. PubMed ID: 23791870
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Laninamivir octanoate: a new long-acting neuraminidase inhibitor for the treatment of influenza.
    Ikematsu H; Kawai N
    Expert Rev Anti Infect Ther; 2011 Oct; 9(10):851-7. PubMed ID: 21973296
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the clinical effectiveness of zanamivir and laninamivir octanoate for children with influenza A(H3N2) and B in the 2011-2012 season.
    Koseki N; Kaiho M; Kikuta H; Oba K; Togashi T; Ariga T; Ishiguro N
    Influenza Other Respir Viruses; 2014 Mar; 8(2):151-8. PubMed ID: 23953886
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro neuraminidase inhibitory activity of four neuraminidase inhibitors against influenza virus isolates in the 2011-2012 season in Japan.
    Ikematsu H; Kawai N; Iwaki N; Kashiwagi S
    J Infect Chemother; 2014 Feb; 20(2):77-80. PubMed ID: 24560563
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influenza Virus Shedding in Laninamivir-Treated Children upon Returning to School.
    Kondo H; Shobugawa Y; Hibino A; Yagami R; Dapat C; Okazaki M; Otsuka T; Fujii K; Hassan MR; Saito R
    Tohoku J Exp Med; 2016 Feb; 238(2):113-21. PubMed ID: 26806610
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-acting neuraminidase inhibitor laninamivir octanoate versus oseltamivir for treatment of influenza: A double-blind, randomized, noninferiority clinical trial.
    Watanabe A; Chang SC; Kim MJ; Chu DW; Ohashi Y;
    Clin Infect Dis; 2010 Nov; 51(10):1167-75. PubMed ID: 20936975
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the clinical effectiveness of oseltamivir and zanamivir against influenza virus infection in children.
    Sugaya N; Tamura D; Yamazaki M; Ichikawa M; Kawakami C; Kawaoka Y; Mitamura K
    Clin Infect Dis; 2008 Aug; 47(3):339-45. PubMed ID: 18582202
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-acting neuraminidase inhibitor laninamivir octanoate (CS-8958) versus oseltamivir as treatment for children with influenza virus infection.
    Sugaya N; Ohashi Y
    Antimicrob Agents Chemother; 2010 Jun; 54(6):2575-82. PubMed ID: 20368393
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A meta-analysis of laninamivir octanoate for treatment and prophylaxis of influenza.
    Higashiguchi M; Matsumoto T; Fujii T
    Antivir Ther; 2018; 23(2):157-165. PubMed ID: 28869418
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical effectiveness of oseltamivir and zanamivir for treatment of influenza A virus subtype H1N1 with the H274Y mutation: a Japanese, multicenter study of the 2007-2008 and 2008-2009 influenza seasons.
    Kawai N; Ikematsu H; Hirotsu N; Maeda T; Kawashima T; Tanaka O; Yamauchi S; Kawamura K; Matsuura S; Nishimura M; Iwaki N; Kashiwagi S
    Clin Infect Dis; 2009 Dec; 49(12):1828-35. PubMed ID: 19911968
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical efficacy of long-acting neuraminidase inhibitor laninamivir octanoate hydrate in postmarketing surveillance.
    Kashiwagi S; Yoshida S; Yamaguchi H; Mitsui N; Tanigawa M; Shiosakai K; Yamanouchi N; Shiozawa T; Yamaguchi F
    J Infect Chemother; 2013 Apr; 19(2):223-32. PubMed ID: 23085742
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of oseltamivir treatment started within 5 days of symptom onset to reduce influenza illness duration and virus shedding in an urban setting in Bangladesh: a randomised placebo-controlled trial.
    Fry AM; Goswami D; Nahar K; Sharmin AT; Rahman M; Gubareva L; Azim T; Bresee J; Luby SP; Brooks WA
    Lancet Infect Dis; 2014 Feb; 14(2):109-18. PubMed ID: 24268590
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.